Ovarian cancer is a common malignant tumor in gynaecology and its mortality rate is the highest in gynecological cancer. Ovarian cancer patients should face platinum resistance, caused by multiple recurrences. According to the platinum-free interval (PFI), recurrent ovarian cancer can be divided into platinum-resistant (PFI<6 months) and platinum-sensitive (PFI≥6 months). When PFI is 6-12 months, it belongs to the partial platinum-sensitive ovarian cancer. At present, how to prolong the survival of patients with partial platinum-sensitive recurrent ovarian cancer is difficult. Secondary cytoreductive surgery, non-platinum chemotherapy, anti-angiogenesis drugs, and molecular targeted therapy of poly (ADP ribose) polymerase (PARP) inhibitors can improve the prognosis of patients with partial platinum-sensitive recurrent ovarian cancer.
卵巢癌是妇科常见的恶性肿瘤，病死率位于妇科恶性肿瘤首位，且多次复发最终导致患者对铂耐药。根据无铂间隔(platinum-free interval，PFI)，可将复发性卵巢癌分为耐药(PFI<6个月)和铂敏感(PFI≥6个月)，其中PFI为6~12个月的被定义为部分铂敏感。目前，如何改善部分铂敏感复发性卵巢癌患者的生存预后是难点。卵巢癌二次减瘤术、非铂类药物化学治疗、抗血管生成药物和多聚ADP核糖聚合酶[poly (ADP-ribose) polymerase，PARP]抑制剂的分子靶向治疗等可改善部分铂敏感复发性卵巢癌患者的预后。.
Keywords: molecular targeted therapy; partial platinum-sensitive; platinum-free interval; recurrent ovarian cancer; secondary cytoreductive surgery.